These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 32599724)

  • 21. Complex interactions in a novel SCN5A compound mutation associated with long QT and Brugada syndrome: Implications for Na+ channel blocking pharmacotherapy for de novo conduction disease.
    Liu J; Bayer JD; Aschar-Sobbi R; Wauchop M; Spears D; Gollob M; Vigmond EJ; Tsushima R; Backx PH; Chauhan VS
    PLoS One; 2018; 13(5):e0197273. PubMed ID: 29791480
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Normalization of ventricular repolarization with flecainide in long QT syndrome patients with SCN5A:DeltaKPQ mutation.
    Windle JR; Geletka RC; Moss AJ; Zareba W; Atkins DL
    Ann Noninvasive Electrocardiol; 2001 Apr; 6(2):153-8. PubMed ID: 11333173
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Rate-dependent QT shortening mechanism for the LQT3 deltaKPQ mutant.
    Nagatomo T; January CT; Ye B; Abe H; Nakashima Y; Makielski JC
    Cardiovasc Res; 2002 Jun; 54(3):624-9. PubMed ID: 12031708
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A revised view of cardiac sodium channel "blockade" in the long-QT syndrome.
    Kambouris NG; Nuss HB; Johns DC; Marbán E; Tomaselli GF; Balser JR
    J Clin Invest; 2000 Apr; 105(8):1133-40. PubMed ID: 10772658
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Arrhythmogenic Biophysical Phenotype for SCN5A Mutation S1787N Depends upon Splice Variant Background and Intracellular Acidosis.
    Hu RM; Tan BH; Tester DJ; Song C; He Y; Dovat S; Peterson BZ; Ackerman MJ; Makielski JC
    PLoS One; 2015; 10(4):e0124921. PubMed ID: 25923670
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Impaired stretch modulation in potentially lethal cardiac sodium channel mutants.
    Banderali U; Juranka PF; Clark RB; Giles WR; Morris CE
    Channels (Austin); 2010; 4(1):12-21. PubMed ID: 20090423
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Predicting Patient Response to the Antiarrhythmic Mexiletine Based on Genetic Variation.
    Zhu W; Mazzanti A; Voelker TL; Hou P; Moreno JD; Angsutararux P; Naegle KM; Priori SG; Silva JR
    Circ Res; 2019 Feb; 124(4):539-552. PubMed ID: 30566038
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Phenotypic characterization of a novel long-QT syndrome mutation (R1623Q) in the cardiac sodium channel.
    Kambouris NG; Nuss HB; Johns DC; Tomaselli GF; Marban E; Balser JR
    Circulation; 1998 Feb; 97(7):640-4. PubMed ID: 9495298
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Long-term flecainide therapy in type 3 long QT syndrome.
    Chorin E; Taub R; Medina A; Flint N; Viskin S; Benhorin J
    Europace; 2018 Feb; 20(2):370-376. PubMed ID: 28339995
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Exploring mutation specific beta blocker pharmacology of the pathogenic late sodium channel current from patient-specific pluripotent stem cell myocytes derived from long QT syndrome mutation carriers.
    Comollo TW; Zou X; Zhang C; Kesters D; Hof T; Sampson KJ; Kass RS
    Channels (Austin); 2022 Dec; 16(1):173-184. PubMed ID: 35949058
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Defining Cardiomyocyte Repolarization Response to Pharmacotherapy in Long-QT Syndrome Type 3.
    Ge N; Li R; Liu M; Xia W; O'Brien ST; McInerney V; Galvin J; Ward D; McGorrian C; O'Brien T; Shen S; Prendiville TW
    J Am Heart Assoc; 2024 Oct; 13(20):e034690. PubMed ID: 39377211
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Autonomic modulation and antiarrhythmic therapy in a model of long QT syndrome type 3.
    Fabritz L; Damke D; Emmerich M; Kaufmann SG; Theis K; Blana A; Fortmüller L; Laakmann S; Hermann S; Aleynichenko E; Steinfurt J; Volkery D; Riemann B; Kirchhefer U; Franz MR; Breithardt G; Carmeliet E; Schäfers M; Maier SK; Carmeliet P; Kirchhof P
    Cardiovasc Res; 2010 Jul; 87(1):60-72. PubMed ID: 20110334
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Differential modulation of late sodium current by protein kinase A in R1623Q mutant of LQT3.
    Tsurugi T; Nagatomo T; Abe H; Oginosawa Y; Takemasa H; Kohno R; Makita N; Makielski JC; Otsuji Y
    Life Sci; 2009 Mar; 84(11-12):380-7. PubMed ID: 19167409
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Structure of human Na
    Li Z; Jin X; Wu T; Zhao X; Wang W; Lei J; Pan X; Yan N
    Proc Natl Acad Sci U S A; 2021 Mar; 118(11):. PubMed ID: 33712541
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The efficacy of Ranolazine on E1784K is altered by temperature and calcium.
    Abdelsayed M; Ruprai M; Ruben PC
    Sci Rep; 2018 Feb; 8(1):3643. PubMed ID: 29483621
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Human iPS cell model of type 3 long QT syndrome recapitulates drug-based phenotype correction.
    Malan D; Zhang M; Stallmeyer B; Müller J; Fleischmann BK; Schulze-Bahr E; Sasse P; Greber B
    Basic Res Cardiol; 2016 Mar; 111(2):14. PubMed ID: 26803770
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Intrinsic mechanism of the enhanced rate-dependent QT shortening in the R1623Q mutant of the LQT3 syndrome.
    Oginosawa Y; Nagatomo T; Abe H; Makita N; Makielski JC; Nakashima Y
    Cardiovasc Res; 2005 Jan; 65(1):138-47. PubMed ID: 15621041
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Altered sinoatrial node function and intra-atrial conduction in murine gain-of-function Scn5a+/ΔKPQ hearts suggest an overlap syndrome.
    Wu J; Zhang Y; Zhang X; Cheng L; Lammers WJ; Grace AA; Fraser JA; Zhang H; Huang CL; Lei M
    Am J Physiol Heart Circ Physiol; 2012 Apr; 302(7):H1510-23. PubMed ID: 22287583
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effects of Allicin on Late Sodium Current Caused by ΔKPQ-SCN5A Mutation in HEK293 Cells.
    Chen Y; Huang Y; Bai J; Liu C; Ma S; Li J; Lu X; Fu Z; Fang L; Li Y; Zhang J
    Front Physiol; 2021; 12():636485. PubMed ID: 33854440
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Functional characterization and identification of a therapeutic for a novel SCN5A-F1760C variant causing type 3 long QT syndrome refractory to all guideline-directed therapies.
    Stutzman MJ; Gao X; Kim M; Ye D; Zhou W; Tester DJ; Giudicessi JR; Shannon K; Ackerman MJ
    Heart Rhythm; 2023 May; 20(5):709-717. PubMed ID: 36731785
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.